An immunohistochemistry and histopathological study of ankaferd blood stopper in a rat model of cervical inflammation

Beyazıt, Fatma; Bűyűk, Başak

doi:10.1590/1806-9282.65.2.183

Cited by 3 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the pathophysiological mechanism of the occurrence and development of cervicitis, the release of a variety of inflammatory factors has become an important risk factor in the development of cervicitis 19 . CP and CRP in the model group increased significantly.…”

Section: Discussionmentioning

confidence: 99%

To explore the therapeutic effect of Kangfuxiaomi shuan II on cervicitis in rats

Duan

et al. 2021

Acta Cir. Bras.

View full text Add to dashboard Cite

The rat cervicitis model was established with 20% phenol glue to explore the therapeutic effect of Kangfuxiaomi shuan II on rat cervicitis and its mechanism. Methods: After modeling, the rats were treated with Shuangzuotai suppository (37.84 mg/kg), Kangfuxiaoyan shuan (205.6 mg/kg) and Kangfuxiaomi shuan II (40, 80, 160 mg/kg). The histopathological changes and injury degree of cervix in rats were evaluated by vulvar inflammation score and organ index. The therapeutic effect of Kangfuxiaomi shuan II on cervicitis was evaluated by detecting the levels of copper-protein (CP), C-reactive protein (CRP), Rat interleukin 6 (IL-6), superoxide dismutase (SOD) and malondialdehyde (MDA) in serum and epidermal growth factor (EGF), cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) in cervical tissue. Results: Compared with the model group, the vulvar inflammation score and cervical index of rats in other groups decreased significantly (P<0.01). Kangfuxiaomi shuan II could significantly reduce the levels of CP, CRP, and MDA in serum of rats with cervicitis, and significantly increase the activity of SOD in serum of rats with cervicitis (P<0.01). The levels of EGF and iNOS in cervical tissue of rats also increased in different degrees, while the level of COX-2 decreased significantly (P<0.01), which significantly improved the pathological degree of vulvar inflammation in rats with cervicitis. Conclusion: Kangfuxiaomi shuan II has a certain therapeutic effect on cervicitis in rats, and its mechanism may be related to the regulation of inflammatory cytokine network and immunity.

show abstract

Section: Discussionmentioning

confidence: 99%

To explore the therapeutic effect of Kangfuxiaomi shuan II on cervicitis in rats

Duan

et al. 2021

Acta Cir. Bras.

View full text Add to dashboard Cite

show abstract

“…Moreover, Dynactin, EGR-1, Midkine, NF-1, Twinfilin, V-Myc, and YY1 (Yin Yang 1) can contribute both the anti-inflammatory and tissue-healing effects of ABS with various mechanisms [46] . Studies also highlight the potential benefits of ABS in numerous distinct inflammatory conditions related to the oral mucosa, intestinal mucosa, cartilage tissue, liver, pericardium, cervix and uterus [19] , [47] , [48] , [49] , [50] , [51] .…”

Section: Evaluation and Discussion Of The Hypothesismentioning

confidence: 99%

Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content

Beyazıt

Tanoğlu³

et al. 2020

Medical Hypotheses

Self Cite

View full text Add to dashboard Cite

COVID-19 due to the SARS-CoV-2 infection is a multi-systemic immune syndrome affecting mainly the lungs, oropharyngeal region, and other vascular endothelial beds. There are tremendous ongoing efforts for the aim of developing drugs against the COVID-19 syndrome-associated inflammation. However, currently no specific medicine is present for the absolute pharmacological cure of COVID-19 mucositis. The re-purposing/re-positioning of already existing drugs is a very important strategy for the management of ongoing pandemy since the development of a new drug needs decades. Apart from altering angiotensin signaling pathways, novel drug candidates for re-purposing comprise medications shall target COVID-19 pathobiology, including pharmaceutical formulations that antagonize proteinase-activated receptors (PARs), mainly PAR-1. Activation of the PAR-1, mediators and hormones impact on the hemostasis, endothelial activation, alveolar epithelial cells and mucosal inflammatory responses which are the essentials of the COVID-19 pathophysiology. In this context, Ankaferd hemostat (Ankaferd Blood Stopper, ABS) which is an already approved hemostatic agent affecting via vital erythroid aggregation and fibrinogen gamma could be a potential topical remedy for the mucosal management of COVID-19. ABS is a clinically safe and effective topical hemostatic agent of plant origin capable of exerting pleiotropic effects on the endothelial cells, angiogenesis, cell proliferation and vascular dynamics. ABS had been approved as a topically applied hemostatic agent for the management of post-surgical/dental bleedings and healing of infected inflammatory mucosal wounds. The anti-inflammatory and proteinase-activated receptor axis properties of ABS with a considerable amount of oestrogenic hormone presence highlight this unique topical hemostatic drug regarding the clinical re-positioning for COVID-19-associated mucositis. Topical ABS as a biological response modifier may lessen SARS-CoV-2 associated microthrombosis, endothelial dysfunction, oropharyngeal inflammation and mucosal lung damage. Moreover, PAR-1 inhibition ability of ABS might be helpful for reducing the initial virus propagation and mocasal spread of COVID-19.

show abstract

“…In a study by Büyüktiryaki et al, ABS decreased the intestinal necrosis in a necrotizing enterocolitis rat model [28]. Beyazit et al reported that ABS reduced inflammation in the developed cervicitis rat model [29]. However, no significant positive effect of ABS was observed on sciatic nerve injury and tendon healing [30,31].…”

Section: Discussionmentioning

confidence: 99%

Histopathological and mechanical effects of Ankaferd Blood Stopper® on wound healing in rats: an experimental model

Hancıoğlu¹,

Demirel²,

Bıçakçı³

et al. 2020

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim To evaluate the histopathological and mechanical effects of Ankaferd Blood Stopper (ABS) application on wound healing. Materials and methods A total of 24 Wistar albino rats were randomly divided into three equal groups. In each group, a 3 cm-long midline vertical skin incision was performed in the back of the rats. In Group 1, the incision was sutured primarily. In Group 2, incision was left to secondary healing. In Group 3, ABS was applied to the incision. On the 10th day, burst pressure width was measured, and rats were sacrificed. The tissue samples were examined histopathologically. Statistical analysis was conducted with IBM SPSS program. P < 0.05 was considered significant. Results The mean burst pressure widths of wound separation were 13.66 ± 0.457, 7.18 ± 2.599, and 13.66 ± 1.11 mm for Groups 1–3, respectively. The difference in burst pressure width between Groups 1 and 3 was not significant (P > 0.05) but was significant between Groups 2 and 3 (P = 0.000). The vascular proliferation median values were 1, 2, and 2, for Groups 1–3, respectively. Although the difference was significant between Groups 1 and 2 in terms of vascular proliferation score (P = 0.047), no significant difference was observed between Group 3 and others. No statistically significant difference was observed among the groups in terms of collagen score, mononuclear cell infiltration, and polymorphonuclear cell proliferation (P > 0.05). The median values of fibroblast proliferation score were 1, 2, and 3, in Groups 1–3, respectively. Fibroblast proliferation score significantly differed between Groups 1 and 3 (P = 0.003). Conclusion ABS application results in a clean wound healing that is as strong as primary repair. However, additional studies are required to evaluate the late results of increased fibroblastic activity in the early period of ABS application alone.

show abstract

An immunohistochemistry and histopathological study of ankaferd blood stopper in a rat model of cervical inflammation

Cited by 3 publications

References 23 publications

To explore the therapeutic effect of Kangfuxiaomi shuan II on cervicitis in rats

To explore the therapeutic effect of Kangfuxiaomi shuan II on cervicitis in rats

Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content

Histopathological and mechanical effects of Ankaferd Blood Stopper® on wound healing in rats: an experimental model

Contact Info

Product

Resources

About